CLL Support Association
9,647 members15,099 posts

Targeted therapy can restore bacterial susceptibility to antibiotics

Targeted therapy can restore bacterial susceptibility to antibiotics

A new targeted therapy drug, which neutralises the enzyme used by bacteria to provide resistance to antibotics, should be ready for human testing in about three years. By targeting a resistance mechanism that's shared by a whole bunch of pathogens, the new drug can make previously antibiotic-resistant bacteria vulnerable to existing drugs again.

Some of the most devastating bacteria get their antibiotic resistance by producing an enzyme known as New Delhi Metallo-beta-lactamase (NDM-1). It's this enzyme that the new research is targeting, by developing a molecule called a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO). This inhibits the bacteria's expression of NDM-1, essentially destroying its antibiotic resistance and allowing existing drugs to be effective once again. :


2 Replies

Sounds like a great reset button!


Do not take travel lightly in the day of drug resistant bacteria.

There are studies of travelers who were tested for Extended Spectrum Beta-Lactamase (ESBLs) after they returned from their travels. ESBL is an enzyme that prevents many antibiotics from being able to kill the bacteria. So the bacteria becomes resistant to the antibiotics or better known as a super bug. The returning travelers can spread ESBLs.

The studies highlight the probability by country traveled to and is quite scary. I have attached a link to The Journal of Travel Medicine:

There are a lot of fascinating, frightening articles. Just google: esbls bacteria travel.


You may also like...